Stockreport

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

Ocugen, Inc.  (OCGN) 
PDF Subsequent to quarter-end, closed $30 million in debt financingOCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) on track to complete enrollment in 1 [Read more]